Medison introduces new breast probe (it's nice and long)
Ultrasound vendor Medison America has introduced a new accessory for its Voluson 530D 3-D ultrasound system, a breast probe that will allow clinicians to visualize lesions, tumors, and other abnormalities as 3-D shapes. The probe consists of an
Ultrasound vendor Medison America has introduced a new accessory for its Voluson 530D 3-D ultrasound system, a breast probe that will allow clinicians to visualize lesions, tumors, and other abnormalities as 3-D shapes. The probe consists of an electronic broadband 5 to 10-MHz transducer with a center frequency of 7.5 MHz.
The probe can be used not only for breast cancer imaging, but also for thyroid and testicular cancer imaging, according to Dennis Wisher, director of ultrasound education. Since the probe is held in one position while it gathers 3-D volume data, it eliminates the need for sonographers to move a transducer over the patients skin, therefore reducing scan time and increasing accuracy, the company said. 3-D images generated by the probe can be rotated, and users can manipulate images with Medisons ultrasound software, which includes niche, transparent, trapezoid, surface rendering, and live 3-D modes.
Philips Launches Flash 5100 Point-of-Care Ultrasound System
June 17th 2025Offering a combination of intuitive touchscreen controls and enhanced image clarity, the portable Flash 5100 POC ultrasound platform reportedly facilitates confident and rapid assessment in emergency radiology and critical care settings.
Ultrasound-Guided Thermal Ablation Shows Low Recurrence of Thyroid Carcinoma at Five Years
June 16th 2025In a meta-analysis involving over 2,200 patients with T1NoMo papillary thyroid carcinoma, researchers noted 2 percent recurrence and no cases of lymph node metastasis five years after ultrasound-guided thermal ablation.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
